Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521178 | 0.84 | ADAM10 (0.49) | SMN1; SMN2ALDH1A1L3MBTL1CCNT1CDK9 | |
| SCHEMBL16385666 | 0.83 | SLC6A4 (0.55) | SMN1; SMN2ALDH1A1SLC6A4ADAM10ERBB2 | |
| SCHEMBL521942 | 0.82 | CCNT1 (0.50) | SMN1; SMN2ALDH1A1CCNT1CDK9SLC6A4 | |
| SCHEMBL520310 | 0.80 | POLB (0.39) | SMN1; SMN2ALDH1A1CCNT1CDK9SLC6A4 | |
| SCHEMBL520126 | 0.78 | PDK4 (0.48) | SMN1; SMN2ALDH1A1CCNT1CDK9ADAM10 | |
| SCHEMBL521338 | 0.73 | HTR6 (0.49) | SMN1; SMN2CYP19A1 | |
| SCHEMBL27932415 | 0.72 | SLC6A4 (0.41) | ALDH1A1SLC6A4ADAM10ERBB2 | |
| SCHEMBL10036180 | 0.71 | ADAM10 (0.47) | SMN1; SMN2ALDH1A1CCNT1CDK9SLC6A4 | |
| SCHEMBL27945231 | 0.70 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL10036445 | 0.69 | ADAM10 (0.46) | ALDH1A1SLC6A4ADAM10ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SMN1; SMN2 4722/4885ALDH1A1 779/4885L3MBTL1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.